Dupixent Charts A Win Before The FDA Prurigo Nodularis Order
Dupixent, the immunology favourite developed by Sanofi and Regeneron Pharmaceuticals, is still on the rise. It has received back-to-back approvals this year for the...
FDA Advisors Help Drug Amylyx For ALS, Altering Prior Stance
A group of Food and Drug Administration advisers has recently come out in favour of a carefully monitored ALS drug, increasing the likelihood that...
With FDA Approval, Revance With Daxxify Will Rival Botox
Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by...
Trodelvy Returns For Gilead In Treatment Of Breast Cancer
After unimpressive evidence on tumour progression, many Gilead Sciences investors have stopped believing in Trodelvy in HR-positive, HER2-negative breast cancer. But now that the...
Anti-Evolocumab Antibodies Are Now Available From Bio-Rad
A group of type 1 antibodies recently made available by Bio-Rad Laboratories are intended to prevent the drug evolcumab from attaching to its target,...
Merck Reviews Five-Year Lung Cancer Studies of Keytruda
By demonstrating a massive survival benefit, Keytruda's Keynote-189 study precipitated a turning point in the development of lung cancer medications. Merck & Co. is...
First Patient Has Been Enrolled In The Sevuparin Experiment
The treatment for paediatric patients with severe malaria is being evaluated through research.
The first patient has been enrolled in the SEVUSMART study, according to...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...